Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. <\/p>\n
Nivalis Therapeutics, Inc. (NASDAQ: NVLS), a pharmaceutical company historically focused on developing innovative solutions for people with cystic fibrosis (CF), today announced topline results from the Company's Phase 2 trial evaluating the efficacy and safety of cavosonstat at a dose of 400 mg in adult patients with CF who had one copy of the F508del-CFTR mutation and a second gating mutation, and were being treated with Kalydeco (ivacaftor). There were no dose limiting toxicities and cavosonstat was well tolerated in the trial. Cavosonstat, when added to Kalydeco therapy, did not demonstrate benefit in absolute change in percent predicted FEV1, the trials primary endpoint, or in sweat chloride reduction at 8 weeks. <\/p>\n
Summary of Key DataThe data announced today are from a Phase 2, double-blind, randomized, placebo controlled, trial that evaluated the efficacy and safety of one dose of cavosonstat administered twice daily (BID) in adult patients with CF who were heterozygous for the F508del-CFTR mutation and a gating mutation, being treated with Kalydeco. The 12-week trial included a total of 19 adults who received treatment with cavosonstat (400 mg) added to Kalydeco (n=15) or with placebo added to Kalydeco (n=4). The trial included a 4-week withdrawal and follow-up period once patients had completed 8 weeks of dosing. <\/p>\n
The primary endpoint of the trial was change in absolute percent predicted FEV1 from baseline to week 8. These primary and key secondary endpoints are shown in the table below. <\/p>\n
Primary and Key Secondary Endpoint at Week 8 <\/p>\n
The increase in body mass index (BMI) reflecting a gain in weight in this study was similar to increases in BMI observed in two prior studies of cavosonstat in CF patients homozygous for F508del-CFTR. In one study, cavosonstat was administered over 4 weeks to CF patients who were not being treated with OrkambiTM and in the other study cavosonstat was administered over 12 weeks to patients who were being treated with Orkambi. End of treatment BMI data from these studies are summarized in the table below. These data suggest that GSNOR inhibition may have improved the nutritional status of patients with CF in these studies. <\/p>\n
We are sincerely grateful to those who participated in this trial, including the patients, their families, the trial investigators and our employees, said Steven Shoemaker, M.D., Medical Director at Nivalis. We hope that the data from this trial will help inform the overall body of CF research, and help others in the design of future CF trials. <\/p>\n
<\/p>\n
Read the rest here: <\/p>\n
Nivalis Therapeutics (NVLS) Says Cavosonstat Phase 2 Clinical ... - StreetInsider.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here Continue reading